Supplemental table 2. Death

|  |  |  |
| --- | --- | --- |
| Variable | HR (95%CI) | p |
| WHOLE COHORT (n=242) |
| No MP | reference |  |
| Out-of-week-2-MP | 2.49 (0.87-7.11) | 0.088 |
| Week-2-MP | 0.48 (0.15-1.57) | 0.225 |
| Non-pulse glucocorticoids | 3.81 (1.52-9.52) | 0.004 |
| Hypertension | 3.34 (1.02-10.94) | 0.047 |
| SaO2/FiO2\* | 0.95 (0.91-0.98) | 0.001 |
| CURB65 |  |  |
| Low risk  | reference |  |
| Intermediate risk | 1.50 (0.49-4.61) | 0.476 |
| High risk  | 7.41 (2.41-22.72) | <0.001 |
| PATIENTS WITH SaO2/FiO2 ≤353 (n=122) |
| No MP | reference |  |
| Out-of-week-2-MP | 2.37 (0.72-7.77) | 0.15 |
| Week-2-MP | 0.41 (0.10-1.66) | 0.2 |
| Non-pulse glucocorticoids | 3.01 (1.27-7.13) | 0.012 |
| Hypertension | 3.56 (1.25-10.1) | 0.017 |
| SaO2/FiO2\* | 0.91 (0.86-0.96) | 0.003 |
| CURB65 | reference |  |
|  | 1.30 (0.34-4.91) | 0.701 |
|  | 10.26 (2.59-40.68) | 0.001 |

MP: methyl-prednisolone pulses; Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI: confidence interval.

\*HR here estimates change in hazard by 10 units increase in SaO2/FiO2. Week-2-MP: methyl-prednisolone pulses in week 2.